$HSTA
Hestia Insight Inc.

2024 Q2 Form 10-Q Financial Statement

#000182912624002685 Filed on April 22, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1 2023 Q1
Revenue $1.241M $38.00K $500.00
YoY Change 4038.0% 7500.0%
Cost Of Revenue
YoY Change
Gross Profit $1.241M $38.00K $500.00
YoY Change 4038.0% 7500.0%
Gross Profit Margin 100.0% 100.0% 100.0%
Selling, General & Admin $91.58K $72.85K $127.3K
YoY Change 6.22% -42.79% -6.28%
% of Gross Profit 7.38% 191.71% 25466.2%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $1.210K $1.212K $6.777K
YoY Change -69.98% -82.12%
% of Gross Profit 0.1% 3.19% 1355.4%
Operating Expenses $91.58K $72.85K $127.3K
YoY Change 6.22% -42.79% -6.28%
Operating Profit $162.6K -$34.85K -$126.8K
YoY Change -389.34% -72.52% -6.65%
Interest Expense $1.581K $375.00
YoY Change -104.12%
% of Operating Profit 0.97%
Other Income/Expense, Net $23.47K $10.15K -$27.08K
YoY Change -137.49% -98.15%
Pretax Income $1.173M -$24.70K -$153.9K
YoY Change -1079.3% -83.95% -90.36%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings $1.173M -$24.70K -$153.9K
YoY Change -1079.3% -83.95% -90.36%
Net Earnings / Revenue 94.51% -65.0% -30782.6%
Basic Earnings Per Share $0.01 $0.00 -$0.01
Diluted Earnings Per Share $0.01 $0.00 -$0.01
COMMON SHARES
Basic Shares Outstanding 27.94M shares 27.94M shares 27.94M shares
Diluted Shares Outstanding 27.94M shares 27.94M shares

Balance Sheet

Concept 2024 Q2 2024 Q1 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.338M $180.3K $391.8K
YoY Change 339.71% -53.99% -47.98%
Cash & Equivalents $61.44K $97.86K $188.8K
Short-Term Investments $1.277M $82.41K $203.0K
Other Short-Term Assets $0.00
YoY Change -100.0%
Inventory
Prepaid Expenses
Receivables $24.00K $8.000K
Other Receivables $0.00 $0.00
Total Short-Term Assets $1.362M $188.3K $391.8K
YoY Change 347.6% -51.95% -50.29%
LONG-TERM ASSETS
Property, Plant & Equipment $25.02K $26.23K $159.8K
YoY Change -75.39% -83.59% 1173.35%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $1.277M $82.41K $203.0K
YoY Change 734.08% -59.41%
Other Assets $0.00
YoY Change
Total Long-Term Assets $25.02K $26.23K $159.8K
YoY Change -75.39% -83.59% 155.52%
TOTAL ASSETS
Total Short-Term Assets $1.362M $188.3K $391.8K
Total Long-Term Assets $25.02K $26.23K $159.8K
Total Assets $1.387M $214.5K $551.6K
YoY Change 241.69% -61.11% -35.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $28.98K $10.69K $21.97K
YoY Change 152.44% -51.34% -7.26%
Accrued Expenses $5.020K
YoY Change -33.33%
Deferred Revenue
YoY Change
Short-Term Debt $53.93K $50.38K $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $82.91K $61.07K $26.98K
YoY Change 467.08% 126.31% -46.61%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $82.91K $61.07K $26.98K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $82.91K $61.07K $26.98K
YoY Change 467.08% 126.31% -51.43%
SHAREHOLDERS EQUITY
Retained Earnings $369.8K -$781.2K -$410.0K
YoY Change -168.07% 90.53%
Common Stock $27.94K $27.94K $27.94K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.304M $153.4K $524.6K
YoY Change
Total Liabilities & Shareholders Equity $1.387M $214.5K $551.6K
YoY Change 241.69% -61.11% -35.16%

Cashflow Statement

Concept 2024 Q2 2024 Q1 2023 Q1
OPERATING ACTIVITIES
Net Income $1.173M -$24.70K -$153.9K
YoY Change -1079.3% -83.95% -90.36%
Depreciation, Depletion And Amortization $1.210K $1.212K $6.777K
YoY Change -69.98% -82.12%
Cash From Operating Activities $1.164M -$46.03K -$91.43K
YoY Change -1382.01% -49.65% 33.37%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$1.204M $0.00 -$155.7K
YoY Change -2359.57% -100.0% -360.39%
Cash From Investing Activities -$1.204M $27.23K
YoY Change -2359.57% -54.47%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.930K $50.00K
YoY Change
NET CHANGE
Cash From Operating Activities 1.164M -$46.03K -$91.43K
Cash From Investing Activities -1.204M $27.23K
Cash From Financing Activities 3.930K $50.00K
Net Change In Cash -36.42K $3.966K -$64.20K
YoY Change -2.83% -106.18% 26.33%
FREE CASH FLOW
Cash From Operating Activities $1.164M -$46.03K -$91.43K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 us-gaap Cost Of Revenue
CostOfRevenue
usd
CY2023Q1 us-gaap Cost Of Revenue
CostOfRevenue
usd
CY2023Q1 us-gaap Interest Expense
InterestExpense
usd
CY2024Q1 us-gaap Debt And Equity Securities Realized Gain Loss
DebtAndEquitySecuritiesRealizedGainLoss
usd
CY2023Q1 HSTA Accounts Receivable And Lease Interest Receivable
AccountsReceivableAndLeaseInterestReceivable
usd
CY2024Q1 HSTA Proceeds Used In Purchase Of Vending Machines
ProceedsUsedInPurchaseOfVendingMachines
usd
CY2024Q1 us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
usd
CY2024Q1 us-gaap Proceeds From Sale Of Equity Method Investments
ProceedsFromSaleOfEquityMethodInvestments
usd
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
CY2023Q1 HSTA Proceeds Provided By Related Party Loan
ProceedsProvidedByRelatedPartyLoan
usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
CY2024Q1 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
usd
CY2023Q1 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
usd
CY2024Q1 HSTA Limitations On Nol Carryforwards Due To Change In Stock Ownership Of Corporation
LimitationsOnNolCarryforwardsDueToChangeInStockOwnershipOfCorporation
usd
CY2023Q1 HSTA Limitations On Nol Carryforwards Due To Change In Stock Ownership Of Corporation
LimitationsOnNolCarryforwardsDueToChangeInStockOwnershipOfCorporation
usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
153425 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
178124 usd
CY2024Q1 us-gaap Revenues
Revenues
38000 usd
CY2024Q1 us-gaap Gross Profit
GrossProfit
38000 usd
CY2023Q1 us-gaap Gross Profit
GrossProfit
500 usd
CY2024Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
72851 usd
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
127331 usd
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
72851 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
127331 usd
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-34851 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-126831 usd
CY2024Q1 us-gaap Interest Income Operating
InterestIncomeOperating
1125 usd
CY2023Q1 us-gaap Interest Income Operating
InterestIncomeOperating
900 usd
CY2023Q1 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
27610 usd
CY2024Q1 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
9402 usd
CY2023Q1 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
-50407 usd
CY2024Q1 us-gaap Interest Expense
InterestExpense
375 usd
CY2023Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
5185 usd
CY2024Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
10152 usd
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-27082 usd
CY2024Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-24699 usd
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-153913 usd
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-0 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-0 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-24699 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-153913 usd
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.001
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.005
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.001
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.005
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27939260 shares
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27939260 shares
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27939260 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27939260 shares
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
178124 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-24699 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
153425 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
678529 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-153913 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
524616 usd
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-24699 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-153912 usd
CY2023Q1 us-gaap Debt And Equity Securities Realized Gain Loss
DebtAndEquitySecuritiesRealizedGainLoss
27610 usd
CY2024Q1 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
9402 usd
CY2023Q1 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-50407 usd
CY2024Q1 us-gaap Depreciation
Depreciation
1212 usd
CY2023Q1 us-gaap Depreciation
Depreciation
6777 usd
CY2023Q1 HSTA Bad Debt Expense
BadDebtExpense
5185 usd
CY2024Q1 HSTA Accounts Receivable And Lease Interest Receivable
AccountsReceivableAndLeaseInterestReceivable
-8000 usd
CY2024Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-5145 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
12277 usd
CY2024Q1 us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
-21335 usd
CY2023Q1 us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
47036 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-46034 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-106876 usd
CY2023Q1 HSTA Proceeds Used In Purchase Of Vending Machines
ProceedsUsedInPurchaseOfVendingMachines
385 usd
CY2023Q1 us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
9170 usd
CY2023Q1 us-gaap Proceeds From Sale Of Equity Method Investments
ProceedsFromSaleOfEquityMethodInvestments
52227 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
42672 usd
CY2024Q1 HSTA Proceeds Provided By Related Party Loan
ProceedsProvidedByRelatedPartyLoan
50000 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
50000 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
3966 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-64204 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
93890 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
252956 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
97856 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
188752 usd
CY2024Q1 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
0 usd
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
0 usd
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_840_eus-gaap--UseOfEstimates_zsGTgcbTTqN7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_861_zj2SXTvN5tZ">Estimates</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The financial statements are prepared on the basis of accounting principles generally accepted in the United States of America, also referred to as U.S. GAAP. The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the dates of the balance sheets and the income and expenses for the periods ended as stated in the statements of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p>
CY2024Q1 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p id="xdx_84D_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zWkUJRNqoeYi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_862_zvNFoarzDKhg">Reclassification of prior year presentation</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cash flows for February 28, 2023, have been reclassified for consistency with current year presentation. These reclassifications had no effect on the reported net decrease in cash as of February 28, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p>
CY2024Q1 us-gaap Equity Method Investment Aggregate Cost
EquityMethodInvestmentAggregateCost
47324 usd
CY2024Q1 us-gaap Increase Decrease In Equity Securities Fv Ni
IncreaseDecreaseInEquitySecuritiesFvNi
9402 usd
CY2024Q1 HSTA Investment In Equities Cumulative Impairments
InvestmentInEquitiesCumulativeImpairments
0 usd
CY2024Q1 HSTA Investment In Equities Prior Cumulative Adjustment
InvestmentInEquitiesPriorCumulativeAdjustment
25681 usd
CY2024Q1 us-gaap Equity Method Investments
EquityMethodInvestments
82407 usd
CY2024Q1 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0 usd
CY2024Q1 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0 usd
CY2024Q1 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0 usd
CY2024Q1 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0 usd
CY2024Q1 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0 usd
CY2024Q1 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
0 usd
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2024Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21 pure
CY2023Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21 pure
CY2024Q1 us-gaap Income Loss From Continuing Operations Before Interest Expense Interest Income Income Taxes Extraordinary Items Noncontrolling Interests Net
IncomeLossFromContinuingOperationsBeforeInterestExpenseInterestIncomeIncomeTaxesExtraordinaryItemsNoncontrollingInterestsNet
-24699 usd
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Interest Expense Interest Income Income Taxes Extraordinary Items Noncontrolling Interests Net
IncomeLossFromContinuingOperationsBeforeInterestExpenseInterestIncomeIncomeTaxesExtraordinaryItemsNoncontrollingInterestsNet
-153913 usd
CY2024Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21 pure
CY2023Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21 pure
CY2024Q1 HSTA Computed Expected Tax Provision Benefit
ComputedExpectedTaxProvisionBenefit
-5187 usd
CY2023Q1 HSTA Computed Expected Tax Provision Benefit
ComputedExpectedTaxProvisionBenefit
-32322 usd
CY2024Q1 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
5187 usd
CY2023Q1 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
32322 usd
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-0 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-0 usd
CY2024Q1 HSTA Lines Of Credit Receivable
LinesOfCreditReceivable
0 usd
CY2023Q4 HSTA Lines Of Credit Receivable
LinesOfCreditReceivable
0 usd
CY2024Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
0 shares
CY2023 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
0 shares
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2024Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2019Q4 HSTA Preferred Stock Cancelled
PreferredStockCancelled
10000000 shares
CY2024Q1 us-gaap Heldtomaturity Securities In Unrealized Loss Positions Qualitative Disclosure Other Fair Value Volatility Rate
HeldtomaturitySecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherFairValueVolatilityRate
0.77 pure
CY2024Q1 HSTA Stock Price
StockPrice
0.50

Files In Submission

Name View Source Status
0001829126-24-002685-index-headers.html Edgar Link pending
0001829126-24-002685-index.html Edgar Link pending
0001829126-24-002685.txt Edgar Link pending
0001829126-24-002685-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
hestialnsightinc_10q.htm Edgar Link pending
hestialnsightinc_ex31-1.htm Edgar Link pending
hestialnsightinc_ex31-2.htm Edgar Link pending
hestialnsightinc_ex32.htm Edgar Link pending
hsta-20240229.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
hsta-20240229_cal.xml Edgar Link unprocessable
hsta-20240229_def.xml Edgar Link unprocessable
hsta-20240229_lab.xml Edgar Link unprocessable
hsta-20240229_pre.xml Edgar Link unprocessable
hestialnsightinc_10q_htm.xml Edgar Link completed
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending